SAFETY PROFILE OF PULSED FIELD ABLATION IN ATRIAL FIBRILLATION: PROCEDURAL COMPLICATIONS, TISSUE SELECTIVITY AND EMERGING CLINICAL CHALLENGES
Keywords:
Atrial fibrillation; pulsed field ablation; safety; complications; coronary spasm; haemolysis; acute kidney injury; catheter ablation.Abstract
Pulsed field ablation (PFA) is a non-thermal catheter-based technique increasingly used for pulmonary vein isolation in patients with atrial fibrillation (AF). Its mechanism, irreversible electroporation, offers relative myocardial tissue selectivity and may reduce several complications associated with thermal ablation. Nevertheless, PFA should not be considered free of procedural risk. This review examines the safety profile of PFA with emphasis on vascular injury, cardiac tamponade, thromboembolic events, coronary artery spasm, haemolysis and acute kidney injury, as well as the reduced occurrence of oesophageal injury, pulmonary vein stenosis and persistent phrenic nerve palsy reported in large registries. The MANIFEST-17K registry, which included 17,642 patients, reported a major complication rate of approximately 1%, with tamponade, vascular events, stroke and coronary spasm among the relevant events. Rare haemolysis-associated renal failure was also identified. These findings demonstrate that PFA changes rather than eliminates the complication profile of AF ablation. Safe implementation requires appropriate patient selection, anticoagulation, vascular-access technique, intraprocedural monitoring and postprocedural surveillance. Continued registry reporting and long-term comparative studies are needed to clarify uncommon adverse events and improve procedural standards.
References
1.Ekanem E, Reddy VY, Gerstenfeld EP, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nature Medicine. 2024;30:2020–2029. doi:10.1038/s41591-024-03114-3.
2.Reddy VY, Gerstenfeld EP, Mountantonakis SE, et al. Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study. Nature Medicine. 2026;32:1444–1453. doi:10.1038/s41591-026-04246-4.
3.Scherr D, Turagam MK, Maury P, et al. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study. Europace. 2025;27(8):euaf012. doi:10.1093/europace/euaf012.
4.Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation. New England Journal of Medicine. 2026;394:2407–2418. doi:10.1056/NEJMoa2600929.
5.Schutyser W, Ector J, De Potter TD, Vandenberk B. Evaluation of pulsed-field ablation for paroxysmal atrial fibrillation: a systematic review. Acta Cardiologica. 2025;81:128–142. (Schutyser et al., 2025)
6.Malik U, Hashmi TA, Bai P, et al. Pulsed field ablation versus high-power short-duration ablation in atrial fibrillation: a systematic and meta-analysis. Cardiology in Review. 2025. (Malik et al., 2025)
7.Kim HJ, Lee CH. Pulsed field ablation: focused on atrial fibrillation ablation. The Korean Journal of Internal Medicine. 2025;41:197–209. (Kim & Lee, 2025)




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal